KEYTRUDA Padcev MIBC Survival: New Era in Treat...

By HEOR Staff Writer

March 2, 2026

KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
National HealthTech Access: Transforming NHS Adoption and Equity
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...